Jagdish Prasad Meena
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jagdish Prasad Meena has a total of 272 co-authors. Here are the top co-authors by number of shared publications:
Rachna Seth
32 shared publications- Aditya Kumar Gupta
Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto, Ontario
26 shared publications Aditya Kumar Gupta
18 shared publicationsPranay Tanwar
9 shared publications- Sameer Bakhshi
Department of Medical Oncology, Dr. B.R.A. Institute of Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
9 shared publications - Rachna Seth
Division of Pediatric Oncology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
8 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (5) , 583
Genomic Characterization of RTK-RAS Pathway Alterations in Juvenile Myelomonocytic Leukemia Through Whole-Exome Sequencing
Background/Objectives: Juvenile myelomonocytic leukemia (JMML) is a rare and very aggressive pediatric myelodysplastic/myeloproliferative neoplasm with molecular heterogeneity and constitutive activation of the RAS signaling pathway. The aim of this study was to identify the mutational landscape, driver genes, mutational signatures, functional pathways, and therapeutic targets of mutations that affect receptor tyrosine kinases (RTKs) and RAS pathways in JMML. Methods: We collected tumor and matched buccal swab samples from 35 patients with JMML and performed whole-exome sequencing. Variants were called using GATK-Mutect2 and annotated with ANNOVAR. Mutational profiling, co-occurrence analysis, protein domain mapping, and driver gene identification were performed using maftools and OncodriveCLUST. DGIdb was used to explore drug–gene interactions, MutationalPatterns was used for the characterization of mutational signatures, and the clusterProfiler package was used for the functional enrichment analyses. Results: Alteration of the RTK-RAS pathway was found in 77.1% of patients. PTPN11 (23%), NRAS (20%), and KRAS (14%) were the most frequently altered genes, followed by PTEN (11%) and FLT3, ROS1, FGFR4, ERBB2, and EGFR (9% each). Domain mapping of protein sequences identified the grouping of mutations within the conserved functional domains of the proteins. The alterations in receptor tyrosine kinase genes demonstrated a significant degree of co-occurrence, while the alterations in canonical JMML genes showed mutual exclusivity. PTPN11, NRAS, ROS1, and FGFR4 were top driver genes based on driver gene analysis. Functional enrichment analysis revealed significant enrichment of receptor tyrosine kinase signaling, Ras/MAPK and PI3K-AKT pathways. The mutational signatures were mostly SBS5-like, with enrichment of C>T transitions, indicative of endogenous mutational processes. Drug–gene interaction analysis identified EGFR, ALK, ROS1, ERBB2, FLT3, FGFR4, and PDGFRA as highly interconnected and potentially actionable therapeutic targets. Conclusions: These findings expand the molecular landscape of JMML and underscore the importance of aberrant RTK-RAS signaling in disease pathogenesis. The identification of recurrent and potentially druggable RTK alterations provides a rationale for future precision medicine approaches in JMML.
- 18 September 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (5) , 583
Open AccessGenomic Characterization of RTK-RAS Pathway Alterations in Juvenile Myelomonocytic Leukemia Through Whole-Exome Sequencing
Background/Objectives: Juvenile myelomonocytic leukemia (JMML) is a rare and very aggressive pediatric myelodysplastic/myeloproliferative neoplasm with molecular heterogeneity and constitutive activation of the RAS signaling pathway. The aim of this study was to identify the mutational landscape, driver genes, mutational signatures, functional pathways, and therapeutic targets of mutations that affect receptor tyrosine kinases (RTKs) and RAS pathways in JMML. Methods: We collected tumor and matched buccal swab samples from 35 patients with JMML and performed whole-exome sequencing. Variants were called using GATK-Mutect2 and annotated with ANNOVAR. Mutational profiling, co-occurrence analysis, protein domain mapping, and driver gene identification were performed using maftools and OncodriveCLUST. DGIdb was used to explore drug–gene interactions, MutationalPatterns was used for the characterization of mutational signatures, and the clusterProfiler package was used for the functional enrichment analyses. Results: Alteration of the RTK-RAS pathway was found in 77.1% of patients. PTPN11 (23%), NRAS (20%), and KRAS (14%) were the most frequently altered genes, followed by PTEN (11%) and FLT3, ROS1, FGFR4, ERBB2, and EGFR (9% each). Domain mapping of protein sequences identified the grouping of mutations within the conserved functional domains of the proteins. The alterations in receptor tyrosine kinase genes demonstrated a significant degree of co-occurrence, while the alterations in canonical JMML genes showed mutual exclusivity. PTPN11, NRAS, ROS1, and FGFR4 were top driver genes based on driver gene analysis. Functional enrichment analysis revealed significant enrichment of receptor tyrosine kinase signaling, Ras/MAPK and PI3K-AKT pathways. The mutational signatures were mostly SBS5-like, with enrichment of C>T transitions, indicative of endogenous mutational processes. Drug–gene interaction analysis identified EGFR, ALK, ROS1, ERBB2, FLT3, FGFR4, and PDGFRA as highly interconnected and potentially actionable therapeutic targets. Conclusions: These findings expand the molecular landscape of JMML and underscore the importance of aberrant RTK-RAS signaling in disease pathogenesis. The identification of recurrent and potentially druggable RTK alterations provides a rationale for future precision medicine approaches in JMML.
- Open Access
- 19 August 2026
- Published by MDPI AG in Epigenomes
- Vol. 10 (3) , 56
Genomic Characterization of Epigenetic Regulator Gene Alterations in Juvenile Myelomonocytic Leukemia Through Whole-Exome Sequencing
Background/Objectives: Juvenile myelomonocytic leukemia (JMML) is a rare, highly aggressive form of pediatric myelodysplastic/myeloproliferative neoplasm characterized by molecular heterogeneity and constitutive activation of the RAS signaling pathway. This study aimed to characterize the mutational landscape, driver genes, mutational signatures, functional pathways, and therapeutic potential of mutated epigenetic regulator genes in JMML. Methods: Tumor and matched buccal swab samples were collected from 35 JMML patients, and whole-exome sequencing was performed. Somatic variants were called with GATK-Mutect2 and annotated with ANNOVAR. maftools and OncodriveCLUST were used for mutational profiling, co-occurrence analysis, driver gene identification, and protein domain mapping. Drug–gene interactions were explored using DGIdb, mutational signatures for genes were characterized by MutationalPatterns, and functional enrichment analysis was performed by the clusterProfiler package. Results: A total of 28 variants were detected in epigenetic regulator genes, with missense mutations being the most common class of variants and a C>T nucleotide substitution pattern being the most frequent. EP300, SETD2, and DNMT3B were the genes most frequently altered, with 8.57% of cases each, followed by ASXL1, BCORL1, ATRX, KMT2A, and TET2 (5.71% each). Driver gene analysis identified ASXL1 as the top candidate driver gene, followed by BCORL1, EP300, and SETD2. Functional enrichment analysis revealed a high number of genes involved in chromatin organization, histone modification, transcriptional regulation, and oncogenic signaling pathways. The mutational signatures identified were SBS5-like, which are dominated by C>T and T>C transitions, indicating endogenous mutational processes. Analysis of drug–gene interactions revealed KMT2A, EP300, and ATRX as the most interconnected and potentially actionable therapeutic targets. Conclusions: This study provides a comprehensive characterization of epigenetic regulator gene alterations in JMML and highlights the importance of epigenetic dysregulation in disease pathogenesis.
- 19 August 2026
- Published by MDPI AG in Epigenomes
- Vol. 10 (3) , 56
Open AccessGenomic Characterization of Epigenetic Regulator Gene Alterations in Juvenile Myelomonocytic Leukemia Through Whole-Exome Sequencing
Background/Objectives: Juvenile myelomonocytic leukemia (JMML) is a rare, highly aggressive form of pediatric myelodysplastic/myeloproliferative neoplasm characterized by molecular heterogeneity and constitutive activation of the RAS signaling pathway. This study aimed to characterize the mutational landscape, driver genes, mutational signatures, functional pathways, and therapeutic potential of mutated epigenetic regulator genes in JMML. Methods: Tumor and matched buccal swab samples were collected from 35 JMML patients, and whole-exome sequencing was performed. Somatic variants were called with GATK-Mutect2 and annotated with ANNOVAR. maftools and OncodriveCLUST were used for mutational profiling, co-occurrence analysis, driver gene identification, and protein domain mapping. Drug–gene interactions were explored using DGIdb, mutational signatures for genes were characterized by MutationalPatterns, and functional enrichment analysis was performed by the clusterProfiler package. Results: A total of 28 variants were detected in epigenetic regulator genes, with missense mutations being the most common class of variants and a C>T nucleotide substitution pattern being the most frequent. EP300, SETD2, and DNMT3B were the genes most frequently altered, with 8.57% of cases each, followed by ASXL1, BCORL1, ATRX, KMT2A, and TET2 (5.71% each). Driver gene analysis identified ASXL1 as the top candidate driver gene, followed by BCORL1, EP300, and SETD2. Functional enrichment analysis revealed a high number of genes involved in chromatin organization, histone modification, transcriptional regulation, and oncogenic signaling pathways. The mutational signatures identified were SBS5-like, which are dominated by C>T and T>C transitions, indicating endogenous mutational processes. Analysis of drug–gene interactions revealed KMT2A, EP300, and ATRX as the most interconnected and potentially actionable therapeutic targets. Conclusions: This study provides a comprehensive characterization of epigenetic regulator gene alterations in JMML and highlights the importance of epigenetic dysregulation in disease pathogenesis.
- Open Access
- 30 June 2026
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 68 (3) , 461-470
Procalcitonin and proadrenomedullin in pediatric acute leukemia: biomarkers for infection and beyond
Background. The clinical utility of procalcitonin (PCT) and proadrenomedullin (ProADM) in children with malignancies remains inadequately characterized. This study was designed to assess baseline PCT and ProADM levels at the time of leukemia diagnosis and to compare their profiles during subsequent episodes of febrile neutropenia (FN). Methods. Children aged 18 years or younger with newly diagnosed acute leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), were prospectively recruited for this study. Serum levels of PCT and ProADM were measured at baseline, prior to the initiation of chemotherapy at the time of diagnosis, and were reassessed during subsequent episodes of FN. Results. A total of 80 children with acute leukemia were prospectively enrolled, with a median age of 5 years (interquartile range [IQR]: 3-7 years). The study population comprised of ALL in 67.5% of cases and AML in 32.5%. At the time of diagnosis, prior to chemotherapy initiation (n=80), the median serum PCT level was 0.19 ng/mL (IQR: 0.07–0.54), while the median ProADM level was 0.04 nmol/L (IQR: 0.01–0.07). Among the 80 patients, 32 children subsequently developed FN and had paired serum samples available for comparative analysis. During FN episodes, both biomarkers showed a significant increase relative to baseline values. Median PCT increased from 0.16 ng/mL (0.08–0.52) at diagnosis to 0.32 ng/mL (0.08–0.50) during FN (P = 0.03), while median ProADM increased from 0.03 nmol/L (0.006–0.05) to 0.41 nmol/L (0.20–0.81) (P < 0.001). At the time of leukemia diagnosis, splenomegaly was the only clinical factor significantly associated with elevated baseline PCT levels (P = 0.010). Subgroup analysis revealed distinct biomarker patterns: in children with ALL, PCT levels remained largely unchanged between diagnosis and FN, possibly reflecting an underlying baseline inflammatory state, whereas ProADM showed a significant rise during FN, suggesting greater specificity for infectious events. In contrast, in AML, both PCT and ProADM increased significantly during FN, indicating their potential utility as infection-related biomarkers in this subgroup. Conclusion. Both PCT and ProADM were significantly elevated in FN when patients with acute leukemia were analyzed as a whole. However, subgroup analysis revealed differing patterns: in ALL, only ProADM remained significantly associated with FN, whereas PCT showed no significant association. In contrast, in AML, both biomarkers were significantly elevated. These findings suggest that ProADM may have greater clinical utility in guiding the management of febrile episodes, particularly in ALL.
- 30 June 2026
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 68 (3) , 461-470
Open AccessProcalcitonin and proadrenomedullin in pediatric acute leukemia: biomarkers for infection and beyond
Background. The clinical utility of procalcitonin (PCT) and proadrenomedullin (ProADM) in children with malignancies remains inadequately characterized. This study was designed to assess baseline PCT and ProADM levels at the time of leukemia diagnosis and to compare their profiles during subsequent episodes of febrile neutropenia (FN). Methods. Children aged 18 years or younger with newly diagnosed acute leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), were prospectively recruited for this study. Serum levels of PCT and ProADM were measured at baseline, prior to the initiation of chemotherapy at the time of diagnosis, and were reassessed during subsequent episodes of FN. Results. A total of 80 children with acute leukemia were prospectively enrolled, with a median age of 5 years (interquartile range [IQR]: 3-7 years). The study population comprised of ALL in 67.5% of cases and AML in 32.5%. At the time of diagnosis, prior to chemotherapy initiation (n=80), the median serum PCT level was 0.19 ng/mL (IQR: 0.07–0.54), while the median ProADM level was 0.04 nmol/L (IQR: 0.01–0.07). Among the 80 patients, 32 children subsequently developed FN and had paired serum samples available for comparative analysis. During FN episodes, both biomarkers showed a significant increase relative to baseline values. Median PCT increased from 0.16 ng/mL (0.08–0.52) at diagnosis to 0.32 ng/mL (0.08–0.50) during FN (P = 0.03), while median ProADM increased from 0.03 nmol/L (0.006–0.05) to 0.41 nmol/L (0.20–0.81) (P < 0.001). At the time of leukemia diagnosis, splenomegaly was the only clinical factor significantly associated with elevated baseline PCT levels (P = 0.010). Subgroup analysis revealed distinct biomarker patterns: in children with ALL, PCT levels remained largely unchanged between diagnosis and FN, possibly reflecting an underlying baseline inflammatory state, whereas ProADM showed a significant rise during FN, suggesting greater specificity for infectious events. In contrast, in AML, both PCT and ProADM increased significantly during FN, indicating their potential utility as infection-related biomarkers in this subgroup. Conclusion. Both PCT and ProADM were significantly elevated in FN when patients with acute leukemia were analyzed as a whole. However, subgroup analysis revealed differing patterns: in ALL, only ProADM remained significantly associated with FN, whereas PCT showed no significant association. In contrast, in AML, both biomarkers were significantly elevated. These findings suggest that ProADM may have greater clinical utility in guiding the management of febrile episodes, particularly in ALL.
- Open Access
- 21 June 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Bevacizumab added to conventional induction chemotherapy for children with high risk neuroblastoma (BRAVEN trial)
Despite advances in multimodal therapy, high-risk neuroblastoma (HR-NB) continues to have poor outcomes. Response to induction chemotherapy is a key predictor of long-term survival, yet intensive multi-agent regimens have not substantially improved prognosis. This study aims to evaluate the efficacy and safety of adding bevacizumab to conventional induction chemotherapy in HR-NB. This prospective, multicenter, randomized controlled trial will enroll newly diagnosed high-risk neuroblastoma patients, randomized to receive either conventional induction chemotherapy alone (control) or bevacizumab plus conventional induction chemotherapy (intervention). Response to induction therapy will be assessed according to standard criteria, and patients achieving a complete or good partial response will proceed to autologous stem cell transplantation (ASCT). All participants will be followed for at least 2 years to evaluate event-free survival (EFS) and overall survival (OS). The primary outcome, response rate, will be reported as a proportion, and EFS and OS will be analyzed using Kaplan-Meier plots and log-rank tests. The secondary outcomes (toxicity and minimal residual disease) will be reported as proportions. Prognostic factors will be evaluated with univariate and multivariate Cox regression analyses. The study aims to demonstrate that adding bevacizumab to conventional induction chemotherapy improves response rates, increases the proportion of patients eligible for autologous stem cell transplantation (ASCT), and improves survival outcomes, with manageable toxicities. This study is registered with the Clinical Trials Registry of India (CTRI/2024/09/074065, dated: 19/09/2024).
- 21 June 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessBevacizumab added to conventional induction chemotherapy for children with high risk neuroblastoma (BRAVEN trial)
Despite advances in multimodal therapy, high-risk neuroblastoma (HR-NB) continues to have poor outcomes. Response to induction chemotherapy is a key predictor of long-term survival, yet intensive multi-agent regimens have not substantially improved prognosis. This study aims to evaluate the efficacy and safety of adding bevacizumab to conventional induction chemotherapy in HR-NB. This prospective, multicenter, randomized controlled trial will enroll newly diagnosed high-risk neuroblastoma patients, randomized to receive either conventional induction chemotherapy alone (control) or bevacizumab plus conventional induction chemotherapy (intervention). Response to induction therapy will be assessed according to standard criteria, and patients achieving a complete or good partial response will proceed to autologous stem cell transplantation (ASCT). All participants will be followed for at least 2 years to evaluate event-free survival (EFS) and overall survival (OS). The primary outcome, response rate, will be reported as a proportion, and EFS and OS will be analyzed using Kaplan-Meier plots and log-rank tests. The secondary outcomes (toxicity and minimal residual disease) will be reported as proportions. Prognostic factors will be evaluated with univariate and multivariate Cox regression analyses. The study aims to demonstrate that adding bevacizumab to conventional induction chemotherapy improves response rates, increases the proportion of patients eligible for autologous stem cell transplantation (ASCT), and improves survival outcomes, with manageable toxicities. This study is registered with the Clinical Trials Registry of India (CTRI/2024/09/074065, dated: 19/09/2024).
- Open Access
Integrated Genomic Profiling of Newly Diagnosed and Relapsed Acute Myeloid Leukemia Identifies Driver Genes, Mutational Signatures, and Therapeutic Targets
Background/Objectives: Acute myeloid leukemia (AML) is a hematologic malignancy of substantial genetic heterogeneity that exhibits clonal growth and blocked differentiation of myeloid progenitor cells in the bone marrow (BM). Genetic alterations play a vital role in the progression, initiation, and recurrence of AML. The aim of this study was to identify the somatic mutational landscape, pathway perturbations, mutational signatures, and druggability of baseline (at diagnosis) and relapsed AML to determine possible treatment options. Methods: Between 2020 and 2026, 120 diagnostic BM or PB samples were prospectively collected from baseline (at diagnosis) AML patients at AIIMS, New Delhi. WES was conducted of 10 BM samples from five baseline (at diagnosis) and five relapsed patients with AML. Somatic variations were identified by GATK-Mutect2 and annotated by ANNOVAR. Driver genes and pathways were analyzed using Maftools, OncodriveCLUST, and clusterProfiler. Extraction of mutational signatures was performed with the help of SigProfilerExtractor, and evaluation of drug–gene interactions was carried out with the help of DGIdb. In addition, RT-PCR was performed to estimate the expression level of TET1. The recurrent TET1 variation was validated using Sanger sequencing and PCR amplification. Results: Missense mutations were the most common variant type in the cohort, and C > T transitions were the predominant nucleotide substitution pattern. There were recurrent mutations in core AML driver genes, including TET1, FLT3, and TP53, and relapsed samples demonstrated increased involvement and complexity of the signaling system. Pathway analysis revealed widespread dysregulation of carcinogenic networks, including RTK-RAS, WNT, TP53, and PI3K signaling. Mutational signature analysis identified COSMIC SBS5, SBS8, and SBS40, which are associated with mechanisms involving oxidative damage. A large number of actionable targets were identified through druggability screening, particularly involving epigenetic regulators and kinase-associated pathways. RT-PCR analysis also supported altered TET1 expression in AML samples. The TET1 A256V variant was detected and experimentally validated. Conclusions: This study highlights the somatic mutational landscape of baseline (at diagnosis) and relapsed AML and identifies recurrent driver genes, altered signaling pathways, mutational signatures, and actionable targets with possible therapeutic relevance. The integration of mutational and expression analyses further supports a potential role for TET1 in AML biology, although the functional significance of specific variants such as A256V remains uncertain.
Open AccessIntegrated Genomic Profiling of Newly Diagnosed and Relapsed Acute Myeloid Leukemia Identifies Driver Genes, Mutational Signatures, and Therapeutic Targets
Background/Objectives: Acute myeloid leukemia (AML) is a hematologic malignancy of substantial genetic heterogeneity that exhibits clonal growth and blocked differentiation of myeloid progenitor cells in the bone marrow (BM). Genetic alterations play a vital role in the progression, initiation, and recurrence of AML. The aim of this study was to identify the somatic mutational landscape, pathway perturbations, mutational signatures, and druggability of baseline (at diagnosis) and relapsed AML to determine possible treatment options. Methods: Between 2020 and 2026, 120 diagnostic BM or PB samples were prospectively collected from baseline (at diagnosis) AML patients at AIIMS, New Delhi. WES was conducted of 10 BM samples from five baseline (at diagnosis) and five relapsed patients with AML. Somatic variations were identified by GATK-Mutect2 and annotated by ANNOVAR. Driver genes and pathways were analyzed using Maftools, OncodriveCLUST, and clusterProfiler. Extraction of mutational signatures was performed with the help of SigProfilerExtractor, and evaluation of drug–gene interactions was carried out with the help of DGIdb. In addition, RT-PCR was performed to estimate the expression level of TET1. The recurrent TET1 variation was validated using Sanger sequencing and PCR amplification. Results: Missense mutations were the most common variant type in the cohort, and C > T transitions were the predominant nucleotide substitution pattern. There were recurrent mutations in core AML driver genes, including TET1, FLT3, and TP53, and relapsed samples demonstrated increased involvement and complexity of the signaling system. Pathway analysis revealed widespread dysregulation of carcinogenic networks, including RTK-RAS, WNT, TP53, and PI3K signaling. Mutational signature analysis identified COSMIC SBS5, SBS8, and SBS40, which are associated with mechanisms involving oxidative damage. A large number of actionable targets were identified through druggability screening, particularly involving epigenetic regulators and kinase-associated pathways. RT-PCR analysis also supported altered TET1 expression in AML samples. The TET1 A256V variant was detected and experimentally validated. Conclusions: This study highlights the somatic mutational landscape of baseline (at diagnosis) and relapsed AML and identifies recurrent driver genes, altered signaling pathways, mutational signatures, and actionable targets with possible therapeutic relevance. The integration of mutational and expression analyses further supports a potential role for TET1 in AML biology, although the functional significance of specific variants such as A256V remains uncertain.
- 20 April 2026
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
Recent Updates on Pediatric Oncological Emergencies and Their Management
Pediatric oncological emergencies are acute, life-threatening complications arising from malignancies or their treatment. Prompt recognition and intervention are essential to prevent significant morbidity and mortality. Pediatric oncological emergencies are categorized as metabolic, structural, hematological, or treatment-related. Structural emergencies include superior mediastinal syndrome, spinal cord compression, and raised intracranial pressure. Metabolic complications such as tumor lysis syndrome (TLS) and hypercalcemia are frequent, with TLS most common in leukemias and high-grade lymphomas. Hematological crises, hyperleukocytosis with leukostasis, and severe cytopenias may result in bleeding or infections. Treatment-related complications like febrile neutropenia and neutropenic enterocolitis (NEC) add further challenges. Effective management requires a multidisciplinary approach that combines early diagnosis, vigilant monitoring, supportive measures, and disease-directed therapy. Recent progress in risk stratification, early warning systems, and intensive supportive care has improved the ability to anticipate and mitigate these crises. Novel diagnostic tools, including point-of-care ultrasonography (POCUS) and laboratory markers, allow for faster identification of high-risk patients, while updated management guidelines provide evidence-based strategies for intervention. This review highlights novel insights and recent updates in the recognition and management of pediatric oncological emergencies.
- 20 April 2026
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
Recent Updates on Pediatric Oncological Emergencies and Their Management
Pediatric oncological emergencies are acute, life-threatening complications arising from malignancies or their treatment. Prompt recognition and intervention are essential to prevent significant morbidity and mortality. Pediatric oncological emergencies are categorized as metabolic, structural, hematological, or treatment-related. Structural emergencies include superior mediastinal syndrome, spinal cord compression, and raised intracranial pressure. Metabolic complications such as tumor lysis syndrome (TLS) and hypercalcemia are frequent, with TLS most common in leukemias and high-grade lymphomas. Hematological crises, hyperleukocytosis with leukostasis, and severe cytopenias may result in bleeding or infections. Treatment-related complications like febrile neutropenia and neutropenic enterocolitis (NEC) add further challenges. Effective management requires a multidisciplinary approach that combines early diagnosis, vigilant monitoring, supportive measures, and disease-directed therapy. Recent progress in risk stratification, early warning systems, and intensive supportive care has improved the ability to anticipate and mitigate these crises. Novel diagnostic tools, including point-of-care ultrasonography (POCUS) and laboratory markers, allow for faster identification of high-risk patients, while updated management guidelines provide evidence-based strategies for intervention. This review highlights novel insights and recent updates in the recognition and management of pediatric oncological emergencies.
- 21 February 2026
- Published by Springer Nature in Endocrine Pathology
- Vol. 37 (1) , 12
Validation of the Reticulin Algorithm for Adrenocortical Neoplasms: Assessing Diagnostic Accuracy Across All Age Groups and Histological Subtypes
- 21 February 2026
- Published by Springer Nature in Endocrine Pathology
- Vol. 37 (1) , 12
Validation of the Reticulin Algorithm for Adrenocortical Neoplasms: Assessing Diagnostic Accuracy Across All Age Groups and Histological Subtypes
- Open Access
- 16 February 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (2)
A double blind RCT to examine the safety and efficacy of Lactobacillus rhamnosus GG in pediatric febrile neutropenia
- 16 February 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (2)
Open AccessA double blind RCT to examine the safety and efficacy of Lactobacillus rhamnosus GG in pediatric febrile neutropenia